Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 3;22(17):9579. doi: 10.3390/ijms22179579

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

ALOS4 does not affect mouse locomotion or produce anxiety-like behaviors. (A,B) Behavior of ICR mice (n = 5) was not affected by intravenous administration with three acute single doses of ALOS4 (30, 90, or 180 mg/kg). Mice tested in the open-field arena for locomotory activity showed no changes in either cumulative central arena area dwell time (A) or total traveled distance, * at p < 0.05 (B). Mice tested in the EPM test for anxiety-like behavior showed no changes in two analyzed parameters (with exception to 180 mg/kg ALOS4 for OE/TE ratio): Open arm time (OT):/Total time (TT) ratio (C); Open entry (OE)/Total entry (TE) ratio (D).